Nature Communications (Jan 2024)
Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase
- Stanley C. Xie,
- Yinuo Wang,
- Craig J. Morton,
- Riley D. Metcalfe,
- Con Dogovski,
- Charisse Flerida A. Pasaje,
- Elyse Dunn,
- Madeline R. Luth,
- Krittikorn Kumpornsin,
- Eva S. Istvan,
- Joon Sung Park,
- Kate J. Fairhurst,
- Nutpakal Ketprasit,
- Tomas Yeo,
- Okan Yildirim,
- Mathamsanqa N. Bhebhe,
- Dana M. Klug,
- Peter J. Rutledge,
- Luiz C. Godoy,
- Sumanta Dey,
- Mariana Laureano De Souza,
- Jair L. Siqueira-Neto,
- Yawei Du,
- Tanya Puhalovich,
- Mona Amini,
- Gerry Shami,
- Duangkamon Loesbanluechai,
- Shuai Nie,
- Nicholas Williamson,
- Gouranga P. Jana,
- Bikash C. Maity,
- Patrick Thomson,
- Thomas Foley,
- Derek S. Tan,
- Jacquin C. Niles,
- Byung Woo Han,
- Daniel E. Goldberg,
- Jeremy Burrows,
- David A. Fidock,
- Marcus C. S. Lee,
- Elizabeth A. Winzeler,
- Michael D. W. Griffin,
- Matthew H. Todd,
- Leann Tilley
Affiliations
- Stanley C. Xie
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne
- Yinuo Wang
- School of Pharmacy, University College London
- Craig J. Morton
- Biomedical Manufacturing Program, CSIRO
- Riley D. Metcalfe
- Center for Structural Biology, Center for Cancer Research, National Cancer Institute
- Con Dogovski
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne
- Charisse Flerida A. Pasaje
- Department of Biological Engineering, Massachusetts Institute of Technology
- Elyse Dunn
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne
- Madeline R. Luth
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Krittikorn Kumpornsin
- Parasites and Microbes Programme, Wellcome Sanger Institute
- Eva S. Istvan
- Division of Infectious Diseases, Department of Medicine, Washington University in St. Louis
- Joon Sung Park
- Research Institute of Pharmaceutical Sciences and Natural Products Research Institute, College of Pharmacy, Seoul National University
- Kate J. Fairhurst
- Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Medical Center
- Nutpakal Ketprasit
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne
- Tomas Yeo
- Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Medical Center
- Okan Yildirim
- Chemical Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Mathamsanqa N. Bhebhe
- School of Chemistry, University of Sydney
- Dana M. Klug
- School of Pharmacy, University College London
- Peter J. Rutledge
- School of Chemistry, University of Sydney
- Luiz C. Godoy
- Department of Biological Engineering, Massachusetts Institute of Technology
- Sumanta Dey
- Department of Biological Engineering, Massachusetts Institute of Technology
- Mariana Laureano De Souza
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Jair L. Siqueira-Neto
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Yawei Du
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne
- Tanya Puhalovich
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne
- Mona Amini
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne
- Gerry Shami
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne
- Duangkamon Loesbanluechai
- Parasites and Microbes Programme, Wellcome Sanger Institute
- Shuai Nie
- Melbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne
- Nicholas Williamson
- Melbourne Mass Spectrometry and Proteomics Facility, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne
- Gouranga P. Jana
- TCG Lifesciences Private Limited
- Bikash C. Maity
- TCG Lifesciences Private Limited
- Patrick Thomson
- School of Chemistry, The University of Edinburgh
- Thomas Foley
- School of Chemistry, The University of Edinburgh
- Derek S. Tan
- Chemical Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center
- Jacquin C. Niles
- Department of Biological Engineering, Massachusetts Institute of Technology
- Byung Woo Han
- Research Institute of Pharmaceutical Sciences and Natural Products Research Institute, College of Pharmacy, Seoul National University
- Daniel E. Goldberg
- Division of Infectious Diseases, Department of Medicine, Washington University in St. Louis
- Jeremy Burrows
- Medicines for Malaria Venture
- David A. Fidock
- Center for Malaria Therapeutics and Antimicrobial Resistance, Columbia University Medical Center
- Marcus C. S. Lee
- Parasites and Microbes Programme, Wellcome Sanger Institute
- Elizabeth A. Winzeler
- Department of Pediatrics, School of Medicine, University of California, San Diego
- Michael D. W. Griffin
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne
- Matthew H. Todd
- School of Pharmacy, University College London
- Leann Tilley
- Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne
- DOI
- https://doi.org/10.1038/s41467-024-45224-z
- Journal volume & issue
-
Vol. 15,
no. 1
pp. 1 – 18
Abstract
Abstract Malaria poses an enormous threat to human health. With ever increasing resistance to currently deployed drugs, breakthrough compounds with novel mechanisms of action are urgently needed. Here, we explore pyrimidine-based sulfonamides as a new low molecular weight inhibitor class with drug-like physical parameters and a synthetically accessible scaffold. We show that the exemplar, OSM-S-106, has potent activity against parasite cultures, low mammalian cell toxicity and low propensity for resistance development. In vitro evolution of resistance using a slow ramp-up approach pointed to the Plasmodium falciparum cytoplasmic asparaginyl-tRNA synthetase (PfAsnRS) as the target, consistent with our finding that OSM-S-106 inhibits protein translation and activates the amino acid starvation response. Targeted mass spectrometry confirms that OSM-S-106 is a pro-inhibitor and that inhibition of PfAsnRS occurs via enzyme-mediated production of an Asn-OSM-S-106 adduct. Human AsnRS is much less susceptible to this reaction hijacking mechanism. X-ray crystallographic studies of human AsnRS in complex with inhibitor adducts and docking of pro-inhibitors into a model of Asn-tRNA-bound PfAsnRS provide insights into the structure-activity relationship and the selectivity mechanism.